{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T10:15:23Z","timestamp":1783160123925,"version":"3.54.6"},"reference-count":136,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T00:00:00Z","timestamp":1779148800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["R01 CA274640"],"award-info":[{"award-number":["R01 CA274640"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000048","name":"American Cancer Society Inc","doi-asserted-by":"publisher","award":["MBGI-23-1030244-01-MBG"],"award-info":[{"award-number":["MBGI-23-1030244-01-MBG"]}],"id":[{"id":"10.13039\/100000048","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000048","name":"American Cancer Society Inc","doi-asserted-by":"publisher","award":["EDS-24-1330440-01-EDS"],"award-info":[{"award-number":["EDS-24-1330440-01-EDS"]}],"id":[{"id":"10.13039\/100000048","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015597","name":"Siebel Scholars Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015597","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000879","name":"Alfred P. Sloan Foundation","doi-asserted-by":"publisher","award":["G-2020-14067"],"award-info":[{"award-number":["G-2020-14067"]}],"id":[{"id":"10.13039\/100000879","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Advanced Drug Delivery Reviews"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.addr.2026.115894","type":"journal-article","created":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T02:22:42Z","timestamp":1778552562000},"page":"115894","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Cowpea mosaic virus as a candidate for intratumoral immunotherapy: progress, challenges, and future directions"],"prefix":"10.1016","volume":"235","author":[{"given":"Ayumi E.","family":"Pottenger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony O.","family":"Omole","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole F.","family":"Steinmetz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.addr.2026.115894_bb0005","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.addr.2026.115894_bb0010","first-page":"10","article-title":"Cancer statistics, 2025","volume":"75","author":"Siegel","year":"2025","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.addr.2026.115894_bb0015","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.43198","article-title":"Global disparities of cancer and its projected burden in 2050","volume":"7","author":"Bizuayehu","year":"2024","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.addr.2026.115894_bb0020","series-title":"Global Cancer observatory: Cancer tomorrow (version 1.1)","author":"Ferlay","year":"2024"},{"key":"10.1016\/j.addr.2026.115894_bb0025","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1016\/j.gendis.2022.02.007","article-title":"Cancer chemotherapy and beyond: current status, drug candidates, associated risks and progress in targeted therapeutics","volume":"10","author":"Anand","year":"2022","journal-title":"Genes Dis."},{"key":"10.1016\/j.addr.2026.115894_bb0030","first-page":"233","article-title":"The global landscape of approved antibody therapies","volume":"5","author":"Lyu","year":"2022","journal-title":"Antib. Ther."},{"key":"10.1016\/j.addr.2026.115894_bb0035","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1016\/j.ymthe.2025.03.005","article-title":"From concept to cure: the evolution of CAR-T cell therapy","volume":"33","author":"Patel","year":"2025","journal-title":"Mol. Ther."},{"key":"10.1016\/j.addr.2026.115894_bb0040","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/s41698-023-00364-1","article-title":"Applications and clinical trial landscape using toll-like receptor agonists to reduce the toll of cancer","volume":"7","author":"Rolfo","year":"2023","journal-title":"NPJ. Precis. Oncol."},{"key":"10.1016\/j.addr.2026.115894_bb0045","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s41416-018-0328-y","article-title":"Cytokines in clinical cancer immunotherapy","volume":"120","author":"Berraondo","year":"2019","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.addr.2026.115894_bb0050","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-3-030-41008-7_1","article-title":"Overview of basic immunology and clinical application","volume":"1244","author":"Stephen","year":"2020","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.addr.2026.115894_bb0055","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1186\/s13045-023-01492-8","article-title":"Challenges and new technologies in adoptive cell therapy","volume":"16","author":"Zhang","year":"2023","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.addr.2026.115894_bb0060","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.2535","article-title":"Estimation of the percentage of US patients with Cancer who are eligible for and respond to checkpoint inhibitor immunotherapy drugs","volume":"2","author":"Haslam","year":"2019","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.addr.2026.115894_bb0065","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1158\/1078-0432.CCR-16-0049","article-title":"Emerging opportunities and challenges in Cancer immunotherapy","volume":"22","author":"Whiteside","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.addr.2026.115894_bb0070","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.immuni.2019.12.011","article-title":"Top 10 challenges in Cancer immunotherapy","volume":"52","author":"Hegde","year":"2020","journal-title":"Immunity"},{"key":"10.1016\/j.addr.2026.115894_bb0075","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1038\/s41416-024-02634-6","article-title":"Redefining cancer research for therapeutic breakthroughs","volume":"130","author":"Yuzhalin","year":"2024","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.addr.2026.115894_bb0080","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1080\/1744666X.2017.1366315","article-title":"Immunotherapy of cancers comes of age","volume":"13","author":"Yousefi","year":"2017","journal-title":"Expert Rev. Clin. Immunol."},{"key":"10.1016\/j.addr.2026.115894_bb0085","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/s13181-021-00833-8","article-title":"A review of Cancer immunotherapy toxicity: immune checkpoint inhibitors","volume":"17","author":"Chhabra","year":"2021","journal-title":"J. Med. Toxicol."},{"key":"10.1016\/j.addr.2026.115894_bb0090","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s13181-021-00835-6","article-title":"A review of Cancer immunotherapy toxicity II: adoptive cellular therapies, kinase inhibitors, monoclonal antibodies, and oncolytic viruses","volume":"18","author":"Chhabra","year":"2022","journal-title":"J. Med. Toxicol."},{"key":"10.1016\/j.addr.2026.115894_bb0095","article-title":"First oncolytic virus approved for melanoma immunotherapy","volume":"5","author":"Pol","year":"2015","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.addr.2026.115894_bb0100","article-title":"Phase 2 study of intratumoral vidutolimod in combination with intravenous cemiplimab in patients with selected advanced cancer or metastatic cancer: trial in progress. EJC","volume":"2","author":"Bhatia","year":"2024","journal-title":"Skin Cancer"},{"key":"10.1016\/j.addr.2026.115894_bb0105","series-title":"Lokon pharma receives FDA fast track designation for LOAd703 for the treatment of pancreatic Cancer","author":"Lokon","year":"2025"},{"key":"10.1016\/j.addr.2026.115894_bb0110","doi-asserted-by":"crossref","first-page":"793","DOI":"10.3390\/ph16060793","article-title":"Current status and challenges of oncolytic Virotherapy for the treatment of glioblastoma","volume":"16","author":"Webb","year":"2023","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.addr.2026.115894_bb0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.jddst.2024.105365","article-title":"Viral therapy for targeted drug delivery to cancers: recent advances, clinical and regulatory perspectives","volume":"92","author":"Dhuri","year":"2024","journal-title":"J. Drug Delivery Sci. Technol."},{"key":"10.1016\/j.addr.2026.115894_bb0120","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1038\/nrd4663","article-title":"Oncolytic viruses: a new class of immunotherapy drugs","volume":"14","author":"Kaufman","year":"2015","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.addr.2026.115894_bb0125","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.4049\/jimmunol.1900742","article-title":"Antibody Opsonization of a TLR9 agonist-containing virus-like particle enhances in situ immunization","volume":"204","author":"Lemke-Miltner","year":"2020","journal-title":"J. Immunol."},{"key":"10.1016\/j.addr.2026.115894_bb0130","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002484","article-title":"Direct and indirect immune effects of CMP-001, a virus-like particle containing a TLR9 agonist","volume":"9","author":"Sabree","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.addr.2026.115894_bb0135","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/0042-6822(72)90436-9","article-title":"Further purification and characterization of threadlike particles associated with the citrus tristeza disease","volume":"50","author":"Bar-Joseph","year":"1972","journal-title":"Virology"},{"key":"10.1016\/j.addr.2026.115894_bb0140","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/0042-6822(89)90361-9","article-title":"Nucleotide sequence and translation of satellite tobacco mosaic virus RNA","volume":"170","author":"Mirkov","year":"1989","journal-title":"Virology"},{"key":"10.1016\/j.addr.2026.115894_bb0145","doi-asserted-by":"crossref","DOI":"10.1002\/wnan.1591","article-title":"From stars to stripes: RNA-directed shaping of plant viral protein templates-structural synthetic virology for smart biohybrid nanostructures","volume":"12","author":"Wege","year":"2020","journal-title":"Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol."},{"key":"10.1016\/j.addr.2026.115894_bb0150","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/978-1-4939-7808-3_11","article-title":"Bottom-up assembly of TMV-based nucleoprotein architectures on solid supports","volume":"1776","author":"Wege","year":"2018","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.addr.2026.115894_bb0155","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1099\/vir.0.024356-0","article-title":"Thermal transition of native tobacco mosaic virus and RNA-free viral proteins into spherical nanoparticles","volume":"92","author":"Atabekov","year":"2011","journal-title":"J. Gen. Virol."},{"key":"10.1016\/j.addr.2026.115894_bb0160","doi-asserted-by":"crossref","DOI":"10.3389\/fpls.2020.594019","article-title":"The emergency response capacity of plant-based biopharmaceutical manufacturing-what it is and what it could be","volume":"11","author":"Tuse","year":"2020","journal-title":"Front. Plant Sci."},{"key":"10.1016\/j.addr.2026.115894_bb0165","article-title":"Plant molecular farming: a viable platform for recombinant biopharmaceutical production","volume":"9","author":"Shanmugaraj","year":"2020","journal-title":"Plants (Basel)"},{"key":"10.1016\/j.addr.2026.115894_bb0170","doi-asserted-by":"crossref","first-page":"5126","DOI":"10.1002\/smll.201400558","article-title":"Loading and release mechanism of red clover necrotic mosaic virus derived plant viral nanoparticles for drug delivery of doxorubicin","volume":"10","author":"Cao","year":"2014","journal-title":"Small"},{"key":"10.1016\/j.addr.2026.115894_bb0175","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.virol.2013.03.001","article-title":"Reconstituted plant viral capsids can release genes to mammalian cells","volume":"441","author":"Azizgolshani","year":"2013","journal-title":"Virology"},{"key":"10.1016\/j.addr.2026.115894_bb0180","first-page":"2501","article-title":"Presentation and delivery of Tumor necrosis factor-related apoptosis-inducing ligand via elongated plant viral nanoparticle enhances antitumor efficacy","volume":"13","author":"Le","year":"2019","journal-title":"ACS Nano"},{"key":"10.1016\/j.addr.2026.115894_bb0185","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0118096","article-title":"Plant virus particles carrying tumour antigen activate TLR7 and induce high levels of protective antibody","volume":"10","author":"Jobsri","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.addr.2026.115894_bb0190","article-title":"Vaccination with nanoparticles combined with micro-adjuvants protects against cancer","volume":"7","author":"Mohsen","year":"2019","journal-title":"J. Immunother. Cancer."},{"key":"10.1016\/j.addr.2026.115894_bb0195","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1021\/acs.nanolett.5b04877","article-title":"Potentiating Cancer immunotherapy using papaya mosaic virus-derived nanoparticles","volume":"16","author":"Lebel","year":"2016","journal-title":"Nano Lett."},{"key":"10.1016\/j.addr.2026.115894_bb0200","series-title":"Cowpea Mosaic Virus. DPVweb: An open access internet resource on plant viruses and virus diseases","author":"Van Kammen","year":"2001"},{"key":"10.1016\/j.addr.2026.115894_bb0205","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1006\/viro.1994.1417","article-title":"Development of cowpea mosaic virus as a high-yielding system for the presentation of foreign peptides","volume":"202","author":"Porta","year":"1994","journal-title":"Virology"},{"key":"10.1016\/j.addr.2026.115894_bb0210","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/978-1-0716-2241-4_7","article-title":"Specific packaging of custom RNA molecules into cowpea mosaic virus-like particles","volume":"2480","author":"Peyret","year":"2022","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.addr.2026.115894_bb0215","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1021\/mp3002057","article-title":"CPMV-DOX Delivers","volume":"10","author":"Aljabali","year":"2013","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.addr.2026.115894_bb0220","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1038\/nnano.2015.292","article-title":"In situ vaccination with cowpea mosaic virus nanoparticles suppresses metastatic cancer","volume":"11","author":"Lizotte","year":"2016","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.addr.2026.115894_bb0225","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005834","article-title":"In situ vaccination with cowpea mosaic virus elicits systemic antitumor immunity and potentiates immune checkpoint blockade","volume":"10","author":"Mao","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.addr.2026.115894_bb0230","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1038\/s42003-024-06982-0","article-title":"Cellular fate of a plant virus immunotherapy candidate","volume":"7","author":"Omole","year":"2024","journal-title":"Commun. Biol."},{"key":"10.1016\/j.addr.2026.115894_bb0235","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1021\/acsptsci.3c00285","article-title":"Pharmacology of a plant virus immunotherapy candidate for peritoneal metastatic ovarian Cancer","volume":"7","author":"Omole","year":"2024","journal-title":"ACS Pharmacol Transl Sci"},{"key":"10.1016\/j.addr.2026.115894_bb0240","doi-asserted-by":"crossref","first-page":"1802281","DOI":"10.1002\/advs.201802281","article-title":"Cowpea mosaic virus immunotherapy combined with cyclophosphamide reduces breast Cancer tumor burden and inhibits lung metastasis","volume":"6","author":"Cai","year":"2019","journal-title":"Adv Sci (Weinh)"},{"key":"10.1016\/j.addr.2026.115894_bb0245","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-004044","article-title":"Neoadjuvant in situ vaccination with cowpea mosaic virus as a novel therapy against canine inflammatory mammary cancer","volume":"10","author":"Alonso-Miguel","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.addr.2026.115894_bb0250","doi-asserted-by":"crossref","DOI":"10.3390\/cells13171478","article-title":"An abscopal effect on lung metastases in canine mammary cancer patients induced by neoadjuvant intratumoral immunotherapy with cowpea mosaic virus nanoparticles and anti-canine PD-1","volume":"13","author":"Sergent","year":"2024","journal-title":"Cells"},{"key":"10.1016\/j.addr.2026.115894_bb0255","doi-asserted-by":"crossref","first-page":"2671","DOI":"10.1021\/acs.molpharmaceut.5c00100","article-title":"Pilot study of intratumoral immunotherapy with cowpea mosaic virus nanoparticles: safety in refractory canine oral tumors","volume":"22","author":"Delgado-Bonet","year":"2025","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.addr.2026.115894_bb0260","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1021\/acs.molpharmaceut.2c00058","article-title":"Cowpea mosaic virus outperforms other members of the Secoviridae as in situ vaccine for Cancer immunotherapy","volume":"19","author":"Beiss","year":"2022","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.addr.2026.115894_bb0265","doi-asserted-by":"crossref","first-page":"100095","DOI":"10.1016\/j.celbio.2025.100095","article-title":"Comparative analyses for plant virus-based cancer immunotherapy drug development","volume":"1","author":"Omole","year":"2025","journal-title":"Cell Biomater"},{"key":"10.1016\/j.addr.2026.115894_bb0390","doi-asserted-by":"crossref","first-page":"5489","DOI":"10.1039\/D0BM01219J","article-title":"The unique potency of cowpea mosaic virus (CPMV) in situ cancer vaccine","volume":"8","author":"Shukla","year":"2020","journal-title":"Biomater. Sci."},{"key":"10.1016\/j.addr.2026.115894_bb0270","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1006\/viro.1999.0038","article-title":"The refined crystal structure of cowpea mosaic virus at 2.8 a resolution","volume":"265","author":"Lin","year":"1999","journal-title":"Virology"},{"key":"10.1016\/j.addr.2026.115894_bb0275","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S0065-3527(03)62004-X","article-title":"Structures of picorna-like plant viruses: implications and applications","volume":"62","author":"Lin","year":"2003","journal-title":"Adv. Virus Res."},{"key":"10.1016\/j.addr.2026.115894_bb0280","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1002\/j.1460-2075.1984.tb01896.x","article-title":"Homologous sequences in non-structural proteins from cowpea mosaic virus and picornaviruses","volume":"3","author":"Franssen","year":"1984","journal-title":"EMBO J."},{"key":"10.1016\/j.addr.2026.115894_bb0285","doi-asserted-by":"crossref","first-page":"7251","DOI":"10.1093\/nar\/12.18.7251","article-title":"Similarity in gene organization and homology between proteins of animal picornaviruses and a plant comovirus suggest common ancestry of these virus families","volume":"12","author":"Argos","year":"1984","journal-title":"Nucleic Acids Res."},{"issue":"Pt 12","key":"10.1016\/j.addr.2026.115894_bb0370","doi-asserted-by":"crossref","first-page":"3109","DOI":"10.1099\/0022-1317-72-12-3109","article-title":"The mechanism of translation of cowpea mosaic virus middle component RNA: no evidence for internal initiation from experiments in an animal cell transient expression system","volume":"72","author":"Belsham","year":"1991","journal-title":"J. Gen. Virol."},{"key":"10.1016\/j.addr.2026.115894_bb0290","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1002\/j.1460-2075.1983.tb01731.x","article-title":"The nucleotide sequence of cowpea mosaic virus B RNA","volume":"2","author":"Lomonossoff","year":"1983","journal-title":"EMBO J."},{"key":"10.1016\/j.addr.2026.115894_bb0295","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1002\/j.1460-2075.1983.tb01525.x","article-title":"Primary structure and gene organization of the middle-component RNA of cowpea mosaic virus","volume":"2","author":"Van Wezenbeek","year":"1983","journal-title":"EMBO J."},{"key":"10.1016\/j.addr.2026.115894_bb0300","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms10113","article-title":"Mechanisms of assembly and genome packaging in an RNA virus revealed by high-resolution cryo-EM","volume":"6","author":"Hesketh","year":"2015","journal-title":"Nat. Commun."},{"key":"10.1016\/j.addr.2026.115894_bb0305","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/0042-6822(62)90222-2","article-title":"Purification and properties of bean pod mottle virus and associated centrifugal and electrophoretic components","volume":"16","author":"Bancroft","year":"1962","journal-title":"Virology"},{"key":"10.1016\/j.addr.2026.115894_bb0310","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/0042-6822(67)90279-6","article-title":"Infectivity of a mixture of cowpea mosaic virus ribonucleoprotein components","volume":"32","author":"Bruening","year":"1967","journal-title":"Virology"},{"key":"10.1016\/j.addr.2026.115894_bb0315","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/0042-6822(71)90063-8","article-title":"Two proteins from cowpea mosaic virus","volume":"46","author":"Wu","year":"1971","journal-title":"Virology"},{"key":"10.1016\/j.addr.2026.115894_bb0320","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/0042-6822(73)90299-7","article-title":"Polyadenylate sequences in the ribonucleic acids of cowpea mosaic virus","volume":"56","author":"El Manna","year":"1973","journal-title":"Virology"},{"key":"10.1016\/j.addr.2026.115894_bb0325","doi-asserted-by":"crossref","DOI":"10.1093\/nar\/5.12.4505","article-title":"A protein linked to the 5\u2032 termini of both RNA components of the cowpea mosaic virus genome","volume":"5","author":"Stanley","year":"1978","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.addr.2026.115894_bb0330","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1111\/j.1432-1033.1978.tb12721.x","article-title":"Protein bound to the genome RNAs of cowpea mosaic virus","volume":"92","author":"Daubert","year":"1978","journal-title":"Eur. J. Biochem."},{"key":"10.1016\/j.addr.2026.115894_bb0335","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/0014-5793(77)80248-2","article-title":"Translation of cowpea mosaic virus RNA in a cell-free extract from wheat germ","volume":"77","author":"Davies","year":"1977","journal-title":"FEBS Lett."},{"key":"10.1016\/j.addr.2026.115894_bb0340","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/0042-6822(79)90104-1","article-title":"Synthesis and proteolytic processing of cowpea mosaic virus proteins in reticulocyte lysates","volume":"96","author":"Pelham","year":"1979","journal-title":"Virology"},{"key":"10.1016\/j.addr.2026.115894_bb0345","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/0006-291X(81)91716-2","article-title":"Comparison of in vivo and in vitro translation of cowpea mosaic virus RNAs","volume":"99","author":"Goldbach","year":"1981","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.addr.2026.115894_bb0350","series-title":"Encyclopedia of Virology","first-page":"569","article-title":"Cowpea mosaic virus","author":"Lomonossoff","year":"2008"},{"key":"10.1016\/j.addr.2026.115894_bb0355","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1038\/286297a0","article-title":"Independent replication and expression of B-component RNA of cowpea mosaic virus","volume":"286","author":"Goldbach","year":"1980","journal-title":"Nature"},{"key":"10.1016\/j.addr.2026.115894_bb0360","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/0042-6822(77)90353-1","article-title":"Location of the gene specifying the smaller protein of the cowpea mosaic virus capsid","volume":"79","author":"Gopo","year":"1977","journal-title":"Virology"},{"key":"10.1016\/j.addr.2026.115894_bb0365","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/0042-6822(78)90412-9","article-title":"Complementation and pseudorecombination between ribonucleic acids from two natural isolates of cowpea mosaic virus (severe subgroup)","volume":"85","author":"Thongmeearkom","year":"1978","journal-title":"Virology"},{"key":"10.1016\/j.addr.2026.115894_bb0375","doi-asserted-by":"crossref","first-page":"5348","DOI":"10.1021\/acs.nanolett.2c01328","article-title":"Cowpea mosaic virus and natural killer cell Agonism for in situ Cancer vaccination","volume":"22","author":"Koellhoffer","year":"2022","journal-title":"Nano Lett."},{"key":"10.1016\/j.addr.2026.115894_bb0380","article-title":"A combination of cowpea mosaic virus and immune checkpoint therapy synergistically improves therapeutic efficacy in three tumor models","volume":"30","author":"Wang","year":"2020","journal-title":"Adv. Funct. Mater."},{"key":"10.1016\/j.addr.2026.115894_bb0385","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2021.120914","article-title":"Cowpea mosaic virus stimulates antitumor immunity through recognition by multiple MYD88-dependent toll-like receptors","volume":"275","author":"Mao","year":"2021","journal-title":"Biomaterials"},{"key":"10.1016\/j.addr.2026.115894_bb0395","doi-asserted-by":"crossref","first-page":"1900003","DOI":"10.1002\/adtp.201900003","article-title":"Cowpea mosaic virus promotes anti-tumor activity and immune memory in a mouse ovarian tumor model","volume":"2","author":"Wang","year":"2019","journal-title":"Adv. Ther."},{"key":"10.1016\/j.addr.2026.115894_bb0400","doi-asserted-by":"crossref","first-page":"3717","DOI":"10.1021\/acs.molpharmaceut.8b00126","article-title":"Treatment of canine Oral melanoma with nanotechnology-based immunotherapy and radiation","volume":"15","author":"Hoopes","year":"2018","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.addr.2026.115894_bb0405","article-title":"Neoadjuvant Intratumoral immunotherapy with cowpea mosaic virus induces local and systemic antitumor efficacy in canine mammary Cancer patients","volume":"12","author":"Valdivia","year":"2023","journal-title":"Cell"},{"key":"10.1016\/j.addr.2026.115894_bb0410","doi-asserted-by":"crossref","first-page":"6206","DOI":"10.1021\/acs.molpharmaceut.4c00507","article-title":"Plant virus Intratumoral immunotherapy with CPMV and PVX elicits durable antitumor immunity in a mouse model of diffuse large B-cell lymphoma","volume":"21","author":"Affonso De Oliveira","year":"2024","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.addr.2026.115894_bb0415","doi-asserted-by":"crossref","first-page":"3700","DOI":"10.1021\/acs.molpharmaceut.8b00316","article-title":"In situ vaccination with cowpea vs tobacco mosaic virus against melanoma","volume":"15","author":"Murray","year":"2018","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.addr.2026.115894_bb0420","doi-asserted-by":"crossref","first-page":"6166","DOI":"10.4049\/jimmunol.164.12.6166","article-title":"M-1\/M-2 macrophages and the Th1\/Th2 paradigm","volume":"164","author":"Mills","year":"2000","journal-title":"J. Immunol."},{"key":"10.1016\/j.addr.2026.115894_bb0425","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1177\/0300985811429314","article-title":"Immunological variation between inbred laboratory mouse strains: points to consider in phenotyping genetically immunomodified mice","volume":"49","author":"Sellers","year":"2012","journal-title":"Vet. Pathol."},{"key":"10.1016\/j.addr.2026.115894_bb0430","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/S0149-7634(00)00027-0","article-title":"The effects of hormones on sex differences in infection: from genes to behavior","volume":"24","author":"Klein","year":"2000","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.addr.2026.115894_bb0435","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1038\/nri.2016.90","article-title":"Sex differences in immune responses","volume":"16","author":"Klein","year":"2016","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.addr.2026.115894_bb0440","doi-asserted-by":"crossref","DOI":"10.3390\/cancers17071054","article-title":"Sex-related differences in immunotherapy toxicities: insights into dimorphic responses","volume":"17","author":"Canzian","year":"2025","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.addr.2026.115894_bb0470","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1566394","article-title":"Immunomodulatory effects of intratumoral cowpea mosaic virus and calreticulin nanoparticles in canine tumors: early results","volume":"16","author":"Singh","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.addr.2026.115894_bb0445","doi-asserted-by":"crossref","first-page":"18315","DOI":"10.1021\/acsnano.2c06143","article-title":"In vivo fate of cowpea mosaic virus in situ vaccine: biodistribution and clearance","volume":"16","author":"Affonso De Oliveira","year":"2022","journal-title":"ACS Nano"},{"key":"10.1016\/j.addr.2026.115894_bb0560","first-page":"14","article-title":"Preclinical SC and IV repeat-dose toxicology of a cowpea mosaic virus \u2013 a cancer immunotherapy candidate","author":"Stern","year":"2025","journal-title":"Toxicol. Rep."},{"key":"10.1016\/j.addr.2026.115894_bb0450","doi-asserted-by":"crossref","first-page":"2994","DOI":"10.1021\/acsnano.9b07865","article-title":"Antibody response against cowpea mosaic viral nanoparticles improves in situ vaccine efficacy in ovarian Cancer","volume":"14","author":"Shukla","year":"2020","journal-title":"ACS Nano"},{"key":"10.1016\/j.addr.2026.115894_bb0455","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11040515","article-title":"Plant virus-like particle in situ vaccine for intracranial glioma immunotherapy","volume":"11","author":"Kerstetter-Fogle","year":"2019","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.addr.2026.115894_bb0460","first-page":"100660G","article-title":"Effect of intra-tumoral magnetic nanoparticle hyperthermia and viral nanoparticle immunogenicity on primary and metastatic cancer","volume":"10066","author":"Hoopes","year":"2017","journal-title":"Proc SPIE Int Soc, Opt. Eng."},{"key":"10.1016\/j.addr.2026.115894_bb0465","first-page":"1006605","article-title":"Hypo-fractionated radiation, magnetic nanoparticle hyperthermia and a viral immunotherapy treatment of spontaneous canine Cancer","volume":"10066","author":"Hoopes","year":"2017","journal-title":"Proc SPIE Int Soc, Opt. Eng."},{"key":"10.1016\/j.addr.2026.115894_bb0475","first-page":"13","article-title":"Remission-stage ovarian cancer cell vaccine with cowpea mosaic virus adjuvant prevents tumor growth","author":"Stump","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.addr.2026.115894_bb0480","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.00129-19","article-title":"Cowpea mosaic virus nanoparticles and empty virus-like particles show distinct but overlapping Immunostimulatory properties","volume":"93","author":"Wang","year":"2019","journal-title":"J. Virol."},{"key":"10.1016\/j.addr.2026.115894_bb0485","doi-asserted-by":"crossref","first-page":"a028480","DOI":"10.1101\/cshperspect.a028480","article-title":"Interferon \u03b3 and its important roles in promoting and inhibiting spontaneous and therapeutic cancer immunity","volume":"11","author":"Alspach","year":"2019","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"10.1016\/j.addr.2026.115894_bb0490","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1080\/02656736.2020.1810333","article-title":"In situ vaccination with nanoparticles for cancer immunotherapy: understanding the immunology","volume":"37","author":"Mao","year":"2020","journal-title":"Int. J. Hyperth."},{"key":"10.1016\/j.addr.2026.115894_bb0495","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.bjid.2015.10.011","article-title":"TLR2 and TLR4 mediated host immune responses in major infectious diseases: a review","author":"Mukherjee","year":"2016","journal-title":"Braz. J. Infect. Dis."},{"key":"10.1016\/j.addr.2026.115894_bb0500","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1038\/nri2868","article-title":"Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns","volume":"10","author":"Bachmann","year":"2010","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.addr.2026.115894_bb0505","first-page":"8","article-title":"Macrophages in immunoregulation and therapeutics","author":"Chen","year":"2023","journal-title":"Sig. Transduct. Target. Ther."},{"key":"10.1016\/j.addr.2026.115894_bb0510","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1111\/imr.13176","article-title":"N1 versus N2 and PMN-MDSC: a critical appraisal of current concepts on tumor-associated neutrophils and new directions for human oncology","volume":"314","author":"Antuamwine","year":"2023","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.addr.2026.115894_bb0515","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1016\/j.cell.2023.02.032","article-title":"A neutrophil response linked to tumor control in immunotherapy","volume":"186","author":"Gungabeesoon","year":"2023","journal-title":"Cell"},{"key":"10.1016\/j.addr.2026.115894_bb0520","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/j.immuni.2019.03.025","article-title":"Shared and distinct functions of type I and type III interferons","volume":"50","author":"Lazear","year":"2019","journal-title":"Immunity"},{"key":"10.1016\/j.addr.2026.115894_bb0525","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1111\/imm.13135","article-title":"Endosomal toll-like receptors play a key role in activation of primary human monocytes by cowpea mosaic virus","volume":"159","author":"Albakri","year":"2020","journal-title":"Immunology"},{"key":"10.1016\/j.addr.2026.115894_bb0530","doi-asserted-by":"crossref","DOI":"10.1021\/acsomega.8b00227","article-title":"Radiation therapy combined with cowpea mosaic virus nanoparticle in situ vaccination initiates immune-mediated tumor regression","volume":"3","author":"Patel","year":"2018","journal-title":"ACS Omega"},{"key":"10.1016\/j.addr.2026.115894_bb0535","first-page":"10","article-title":"Cowpea mosaic virus nanoparticle enhancement of hypofractionated radiation in a B16 murine melanoma model","author":"KEA","year":"2020","journal-title":"Front. Oncol."},{"key":"10.1016\/j.addr.2026.115894_bb0540","doi-asserted-by":"crossref","first-page":"4878","DOI":"10.1039\/D4MA00427B","article-title":"Combination of cowpea mosaic virus (CPMV) intratumoral therapy and oxaliplatin chemotherapy","volume":"5","author":"Moreno-Gonzalez","year":"2024","journal-title":"Mater Adv"},{"key":"10.1016\/j.addr.2026.115894_bb0545","doi-asserted-by":"crossref","first-page":"3747","DOI":"10.1021\/acs.molpharmaceut.4c01539","article-title":"Intratumoral immunotherapy with cowpea mosaic virus and Interleukin-12 eliminates established treated tumors and generates robust systemic immunity to suppress the growth of untreated metastatic tumors","volume":"22","author":"Misiaszek","year":"2025","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.addr.2026.115894_bb0550","doi-asserted-by":"crossref","DOI":"10.1007\/s00262-024-03636-2","article-title":"Synergistic combination therapy using cowpea mosaic virus intratumoral immunotherapy and Lag-3 checkpoint blockade","volume":"73","author":"Karan","year":"2024","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.addr.2026.115894_bb0555","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.jconrel.2007.04.003","article-title":"Bio-distribution, toxicity and pathology of cowpea mosaic virus nanoparticles in vivo","volume":"120","author":"Singh","year":"2007","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2026.115894_bb0565","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.jconrel.2013.05.025","article-title":"Understanding the correlation between in vitro and in vivo immunotoxicity tests for nanomedicines","volume":"172","author":"Dobrovolskaia","year":"2013","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2026.115894_bb0570","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.jconrel.2021.08.048","article-title":"Complement opsonization of nanoparticles: differences between humans and preclinical species","volume":"338","author":"Li","year":"2021","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2026.115894_bb0575","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1104\/pp.108.126284","article-title":"Extremely high-level and rapid transient protein production in plants without the use of viral replication","volume":"148","author":"Sainsbury","year":"2008","journal-title":"Plant Physiol."},{"key":"10.1016\/j.addr.2026.115894_bb0580","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1039\/D0MA00752H","article-title":"In situ vaccine application of inactivated CPMV nanoparticles for cancer immunotherapy","volume":"2","author":"Chariou","year":"2021","journal-title":"Mater Adv"},{"key":"10.1016\/j.addr.2026.115894_bb0585","article-title":"Inactivated Cowpea Mosaic Virus for in situ vaccination: differential efficacy of Formalin vs UV-inactivated formulations","volume":"20","author":"Jung","year":"2022","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.addr.2026.115894_bb0590","doi-asserted-by":"crossref","first-page":"5013","DOI":"10.1111\/pbi.70281","article-title":"Toward translation of cowpea mosaic virus Intratumoral immunotherapy with a scalable production process","volume":"23","author":"Opdensteinen","year":"2025","journal-title":"Plant Biotechnol. J."},{"key":"10.1016\/j.addr.2026.115894_bb0595","doi-asserted-by":"crossref","DOI":"10.3389\/fceng.2021.737010","article-title":"Nicotiana spp. for the expression and purification of functional IgG3 antibodies directed against the Staphylococcus aureus alpha toxin","volume":"3","author":"Opdensteinen","year":"2021","journal-title":"Front. Chem. Eng"},{"key":"10.1016\/j.addr.2026.115894_bb0600","series-title":"USP-NF","article-title":"Chapter <85> Bacterial Endotoxins Test","year":"2017"},{"key":"10.1016\/j.addr.2026.115894_bb0605","doi-asserted-by":"crossref","DOI":"10.1002\/btm2.10693","article-title":"Cowpea mosaic virus intratumoral immunotherapy maintains stability and efficacy after long-term storage","volume":"9","author":"Simms","year":"2024","journal-title":"Bioeng. Transl. Med."},{"key":"10.1016\/j.addr.2026.115894_bb0610","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1080\/17435889.2025.2544522","article-title":"Storage stability of cowpea mosaic virus cancer drug candidate - a two-year update","volume":"20","author":"Simms","year":"2025","journal-title":"Nanomedicine (London)"},{"key":"10.1016\/j.addr.2026.115894_bb0635","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1038\/s44222-024-00231-z","article-title":"Virus nanotechnology for intratumoural immunotherapy","volume":"2","author":"Omole","year":"2024","journal-title":"Nat Rev Bioeng"},{"key":"10.1016\/j.addr.2026.115894_bb0640","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s00262-017-2076-x","article-title":"A filamentous bacteriophage targeted to carcinoembryonic antigen induces tumor regression in mouse models of colorectal cancer","volume":"67","author":"Murgas","year":"2018","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.addr.2026.115894_bb0615","doi-asserted-by":"crossref","first-page":"6493","DOI":"10.1039\/D5MA00215J","article-title":"Efficacy of PVX and PEGylated PVX as intratumoral immunotherapy","volume":"6","author":"Ma","year":"2025","journal-title":"Mater Adv"},{"key":"10.1016\/j.addr.2026.115894_bb0620","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1021\/sb300052u","article-title":"Refactored M13 bacteriophage as a platform for tumor cell imaging and drug delivery","volume":"1","author":"Ghosh","year":"2012","journal-title":"ACS Synth. Biol."},{"key":"10.1016\/j.addr.2026.115894_bb0625","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1056\/NEJMoa1716435","article-title":"Recurrent glioblastoma treated with recombinant poliovirus","volume":"379","author":"Desjardins","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.addr.2026.115894_bb0630","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1200\/JCO.2017.75.8219","article-title":"Phase I study of DNX-2401 (Delta-24-RGD) oncolytic adenovirus: replication and immunotherapeutic effects in recurrent malignant glioma","volume":"36","author":"Lang","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.addr.2026.115894_bb0645","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s11816-023-00821-0","article-title":"Plant-made pharmaceuticals: exploring studies for the production of recombinant protein in plants and assessing challenges ahead","volume":"17","author":"Lee","year":"2023","journal-title":"Plant Biotechnol. Rep."},{"key":"10.1016\/j.addr.2026.115894_bb0650","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/256135","article-title":"Manufacturing economics of plant-made biologics: case studies in therapeutic and industrial enzymes","volume":"2014","author":"Tus\u00e9","year":"2014","journal-title":"Biomed. Res. Int."},{"key":"10.1016\/j.addr.2026.115894_bb0655","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1111\/pbi.12469","article-title":"Commercial-scale biotherapeutics manufacturing facility for plant-made pharmaceuticals","volume":"13","author":"Holtz","year":"2015","journal-title":"Plant Biotechnol. J."},{"key":"10.1016\/j.addr.2026.115894_bb0660","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/bs.mie.2021.05.011","article-title":"Manufacturing plant-made monoclonal antibodies for research or therapeutic applications","volume":"660","author":"Swope","year":"2021","journal-title":"Methods Enzymol."},{"key":"10.1016\/j.addr.2026.115894_bb0665","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1177\/2211068212460037","article-title":"Automated production of plant-based vaccines and pharmaceuticals","volume":"17","author":"Wirz","year":"2012","journal-title":"J. Lab. Autom."},{"key":"10.1016\/j.addr.2026.115894_bb0670","doi-asserted-by":"crossref","first-page":"3589","DOI":"10.1021\/acs.molpharmaceut.3c00214","article-title":"The potency of cowpea mosaic virus particles for Cancer in situ vaccination is unaffected by the specific Encapsidated viral RNA","volume":"20","author":"Jung","year":"2023","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.addr.2026.115894_bb0675","doi-asserted-by":"crossref","DOI":"10.1111\/pai.13889","article-title":"Allergenic risk assessment of cowpea and its cross-reactivity with pea and peanut","volume":"33","author":"Chentouh","year":"2022","journal-title":"Pediatr. Allergy Immunol."},{"key":"10.1016\/j.addr.2026.115894_bb0680","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1111\/pbi.70294","article-title":"Nicotiana benthamiana as a source of cowpea mosaic virus-derived particles that specifically package designer RNAs","volume":"24","author":"Peyret","year":"2025","journal-title":"Plant Biotechnol. J."}],"container-title":["Advanced Drug Delivery Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169409X26001286?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169409X26001286?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T09:17:50Z","timestamp":1783156670000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169409X26001286"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":136,"alternative-id":["S0169409X26001286"],"URL":"https:\/\/doi.org\/10.1016\/j.addr.2026.115894","relation":{},"ISSN":["0169-409X"],"issn-type":[{"value":"0169-409X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cowpea mosaic virus as a candidate for intratumoral immunotherapy: progress, challenges, and future directions","name":"articletitle","label":"Article Title"},{"value":"Advanced Drug Delivery Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.addr.2026.115894","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"115894"}}